International Journal of Molecular Sciences· 2026Q1
RNA Interference-Mediated Suppression of RAGE
- 0citations
- Q1SCImago
- 2026year
Short summary
Researchers developed and validated short hairpin RNA (shRNA) constructs (sh1 and sh2) that effectively suppress the receptor for advanced glycation end products (RAGE), a key mediator of aging-related inflammation, by over 70% at mRNA, protein, and cell-surface levels in human cell models.
AI-generated from the title and abstract; the full text is not read.
Key points
- Five shRNA constructs targeting human AGER/RAGE were designed and cloned.
- sh1 and sh2 constructs achieved significant AGER/RAGE knockdown (>70% in some models).
- Suppression was confirmed at mRNA, protein, and cell-surface levels.
- A workflow for screening and validating lentiviral shRNA constructs was established.
AI-generated from the title and abstract; the full text is not read.
Abstract
The receptor for advanced glycation end products (RAGE/AGER) is an important mediator of inflammatory signaling and has been implicated in chronic low-grade inflammation associated with aging. Chronic low-grade inflammation (“inflammaging”) is a characteristic feature of biological aging, providing a rationale for investigating molecular regulators of inflammatory signaling such as RAGE. This study aimed to develop and validate short hairpin RNA (shRNA) constructs suppressing AGER/RAGE in human cell models. Five shRNA constructs targeting human AGER were designed, cloned into pLSL-puro, and verified by Sanger sequencing. Lentiviral vectors were produced in HEK293T cells and used to establish stable HEK293T, 786-O, and human umbilical vein endothelial cell (HUVEC) populations with AGER knockdown. AGER/RAGE expression was assessed by RT-qPCR, Western blotting, and flow cytometry. Silencing efficiency varied with the construct and the cellular model. sh1 produced the strongest suppression of AGER, exceeding 70% in selected models, whereas sh2 was effective in HEK293T and 786-O cells. Reduced RAGE expression was confirmed at the mRNA, protein, and cell-surface levels, identifying sh1 and sh2 as lead candidates. An AGER-focused workflow for lentiviral shRNA construct screening and experimental validation was established, providing a reproducible approach for generating stable cell models with reduced AGER/RAGE expression. Further work is required to confirm isoform specificity, assess off-target effects, and define the functional consequences of RAGE suppression.
The authors' abstract, as published at the source. International Journal of Molecular Sciences, 2026 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Clinical Biochemistry
Clinical BiochemistryBiochemistry, Genetics and Molecular Biology